For example,
High dose efluelda vaccine back:
Reserved for over 65s. Therefore, it was no longer marketed in France because of a disagreement between the French authorities and its manufacturer, Sanofi. Therefore, He will be available again, and supported, for the next anti-grip-taught vaccination campaign.
Will it better contain the winter flu epidemic for winter to come after a particularly difficult 2024-2025 season? Moreover, The EFLUELDA anti-grilled vaccine. Therefore, specifically developed to better protect the elderly more at risk of complications, returns high dose efluelda vaccine back to the French market, according to a decree published Thursday in the Official Journal. It had not been marketed in the last season due to a disagreement between the state. the Sanofi pharmaceutical laboratory on the price. Four times more dosed than the classic vaccine developed by Sanofi against flu. says Vaxigriptetra, Efluelda is reserved for over 65, whose immune system responds less effectively to vaccination.
“The return of Efluelda in trivalent form constitutes a major advance. ” Sanofi told AFP, who “anticipated its production in March” to guarantee its availability for the 2025/26 season. “It will be 100 % reimbursed for populations defined by vaccination recommendations. via a health insurance care voucher, such as other influenza vaccines,” added the group.
Pass advertising
HAS recommendation – High dose efluelda vaccine back
In April 2024. the French health authorities, which the pharmaceutical giant accused of having set a price too low for Efluelda, high dose efluelda vaccine back had announced the stopping of the marketing of this vaccine which continued to be available in more than a dozen countries. They then did not judge that the vaccine had a convincing interest in relation to other vaccines. and therefore did not recommend it more than the others. But last May. at the end of a particularly violent epidemic, the High Authority for Health (HAS) recommended favoring two anti-grip vaccines among the oldest, including Efluelda, compared to the injectable vaccines at standard dose.
The Epidemia 2024/2025 of influenza had indeed revealed particularly violent. with a high mortality from previous years, pushing the HAS to revise its position, especially since the vaccines in circulation testified only to limited efficiency in the elderly.
Further reading: Behind the scenes of an expert center in psychiatry – a high-tech ally towards a tobacco-free life – A first blood test to detect approved Alzheimer’s disease – Video – “He saved my life”: Foie grafted, Jean -Serge renovates the house he thought never again again – The cat is definitely not the best friend of the man.
